PLK1 and non-small cell lung carcinoma: The combination of PLK1 inhibitors with other drugs was also studied in solid tumors, but so far, they have not gone beyond Phase I. The combination of volasertib with pemetrexed for advanced/metastatic NSCLC did not have any greater toxicity, but did not improve the efficacy compared with pemetrexed single-agent (133).